Delivering quality therapy since 1901

Announcements

 

 

Extraordinary announcement - Correction1912<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-10-01T22:00:00Z10/2/2018 12:44:03 PM363http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 1905<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-09-30T22:00:00Z10/1/2018 1:00:45 PM350http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Amendment to the 6 months to June 2018 Report to the Budapest Stock Exchange1909<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>The Company's Board of Directors informs its shareholders that, the following two amendments are being made as of today to the 6 months to June 2018 Report to the Budapest Stock Exchange published on 2 August 2018.​</p>2018-09-30T22:00:00Z10/1/2018 6:58:46 PM332http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Pharmafarm SA re-obtains business licence from Romanian NAMMD1885<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) announces today that with effect from 18 September 2018 the Romanian National Agency for Medicines and Medical Devices (NAMMD) granted the licence to operate of Pharmafarm SA (&quot;Pharmafarm&quot;), Richter's wholesaler subsidiary again. Most of our warehousing facilities have already re-obtained their licence.</p>2018-09-18T22:00:00Z9/19/2018 6:01:02 AM457http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter signed a license and distribution agreement to enhance its fertility portfolio 1881<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announced that it has entered into a license and distribution agreement with L.D. Collins &amp; Co. Limited<br> (&quot;L.D. Collins&quot;), a UK based company, to commercialize its 400mg progesterone containing assisted reproduction technology (ART) product, Cyclogest<sup>®</sup> in&#160; 27 EU countries. Marketing authorizations have already been granted in the above territory. Following the transfer of the marketing authorization holder to Richter, the launch of the product is expected to be executed from early 2019. </p>2018-09-17T22:00:00Z9/18/2018 5:47:37 AM601http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter and Mithra signed a license and supply agreement for commercialization of Estelle®, a novel oral contraceptive1879<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​Gedeon Richter Plc. (hereinafter&#58; &quot;<em>Richter</em>&quot;) and Mithra Pharmaceuticals (hereinafter&#58; &quot;<em>Mithra</em>&quot;) today announced that they have entered into a license and supply agreement to commercialize Estelle<sup>®</sup>, a combined oral contraceptive, containing 15 mg estetrol (E4) / 3 mg drospirenone. &#160;Richter is going to commercialize the product under a different brand name. The product is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues combined with drospirenone's non contraceptive benefits. The geographic scope of the agreement covers Europe and Russia.</p>2018-09-11T22:00:00Z9/12/2018 5:52:31 AM268http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 1873<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-09-02T22:00:00Z9/3/2018 2:10:41 PM154http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
U.S. Food and Drug Administration issues Complete Response Letter for Ulipristal Acetate New Drug Application1867<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.00000000000<p>​Gedeon Richter Plc. hereby informs its shareholders that Allergan Plc. made the following statements in respect of the FDA response to their New Drug Application for ulipristal acetate&#58;</p>2018-08-21T22:00:00Z8/22/2018 6:29:45 AM313http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement1037<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-08-16T22:00:00Z8/17/2018 3:36:04 PM1720http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter Group Report - 6 months to June 2018 1863<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-08-01T22:00:00Z8/2/2018 6:47:58 AM5170http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx